Cargando…
Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
Renal cell carcinoma (RCC) accounts for 3% of all malignancies, and is the most aggressive cancer of the genitourinary system. Metastatic RCC is naturally resistant to chemotherapy and radiotherapy, and immunotherapy is of little benefit. In recent years, the emergence of molecular-targeted therapie...
Autores principales: | Ye, Ding-Wei, Zhang, Hai-Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057324/ https://www.ncbi.nlm.nih.gov/pubmed/24944516 http://dx.doi.org/10.2147/OTT.S41828 |
Ejemplares similares
-
Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma
por: Pan, Jen-Jung, et al.
Publicado: (2010) -
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013) -
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011) -
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma
por: Zustovich, Fable, et al.
Publicado: (2011) -
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study
por: Zhang, Hai-Liang, et al.
Publicado: (2015)